Akorn, Inc. agreed to pay nearly $8m admitting it delayed applications to convert formulations of three of its generic drugs from Rx to nonprescription after the US Food and Drug Administration had approved full OTC switches for brands in the same formulations, leading to improper Medicare payments for the firm's products.
Akorn, which in 2021 divested almost all of its OTC portfolio, continued offering diclofenac sodium 1%, olopatadine hydrochloride 0.1%...







